Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.

Susarla SK, Gupta M, Mantan M, Dhongade R, Bhave S, Das RK, Ray RK, Ramesh Babu T, Ravi MD, Krishnamurthy B, James S, Sandhya G, Satish M, Sahoo DP.

Vaccine. 2019 Aug 23;37(36):5452-5459. doi: 10.1016/j.vaccine.2019.06.067. Epub 2019 Jul 19.

PMID:
31331773
2.

Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants.

Gandhi DJ, Dhaded SM, Ravi MD, Dubey AP, Kundu R, Lalwani SK, Chhatwal J, Mathew LG, Gupta M, Sharma SD, Bavdekar SB, Jayanth MV, Ravinuthala S, Sil A, Dhingra MS.

Hum Vaccin Immunother. 2016 Apr 2;12(4):946-54. doi: 10.1080/21645515.2015.1100779. Epub 2015 Nov 18.

3.

A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.

Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, Lattanzi M.

Hum Vaccin Immunother. 2013 Sep;9(9):1903-9. doi: 10.4161/hv.25166. Epub 2013 Jun 19.

4.

A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants.

Mohanty L, Sharma S, Behera B, Panwar S, Paliwal C, Gupta A, Chilkoti DC, Singh A.

Vaccine. 2018 Apr 19;36(17):2378-2384. doi: 10.1016/j.vaccine.2017.09.029. Epub 2018 Mar 23.

PMID:
29580640
5.

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants.

Mohanty L, Sharma S, Behera B, Panwar S, Paliwal C, Singh A, Gupta A, Chilkoti DC.

Hum Vaccin Immunother. 2017 Sep 2;13(9):2025-2031. doi: 10.1080/21645515.2017.1342020. Epub 2017 Jul 12.

6.

Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.

Sharma H, Yadav S, Lalwani S, Kapre S, Jadhav S, Parekh S, Palkar S, Ravetkar S, Bahl S, Kumar R, Shewale S.

Vaccine. 2013 Jan 7;31(3):444-7. doi: 10.1016/j.vaccine.2012.11.038. Epub 2012 Nov 27.

PMID:
23196204
7.

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.

Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, Verma V.

Hum Vaccin. 2011 Apr;7(4):451-7. Epub 2011 Apr 1.

PMID:
21403463
8.

A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.

Dalvi S, Kulkarni PS, Phadke MA, More SS, Lalwani SK, Jain D, Manglani M, Garg BS, Doibale MK, Deshmukh CT; SIIL DTwP + HepB Hib Author Group.

Hum Vaccin Immunother. 2015;11(4):901-7. doi: 10.1080/21645515.2015.1010953. Erratum in: Hum Vaccin Immunother. 2015;11(7):1879.

9.

Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.

Saluja T, Palkar S, Misra P, Gupta M, Venugopal P, Sood AK, Dhati RM, Shetty A, Dhaded SM, Agarkhedkar S, Choudhury A, Kumar R, Balasubramanian S, Babji S, Adhikary L, Dupuy M, Chadha SM, Desai F, Kukian D, Patnaik BN, Dhingra MS.

Vaccine. 2017 Jun 16;35(28):3575-3581. doi: 10.1016/j.vaccine.2017.05.019. Epub 2017 May 20.

PMID:
28536027
10.

DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.

Gunardi H, Rusmil K, Fadlyana E, Soedjatmiko, Dhamayanti M, Sekartini R, Tarigan R, Satari HI, Medise BE, Sari RM, Bachtiar NS, Kartasasmita CB, Hadinegoro SRS.

BMC Pediatr. 2018 May 28;18(1):177. doi: 10.1186/s12887-018-1143-6.

11.
12.

Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.

Capeding MR, Jica C, Macura-Biegun A, Rauscher M, Alberto E.

Vaccine. 2014 Feb 7;32(7):888-94. doi: 10.1016/j.vaccine.2013.10.059. Epub 2013 Oct 29.

13.

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW.

Vaccine. 2016 Jul 19;34(33):3810-6. doi: 10.1016/j.vaccine.2016.05.054. Epub 2016 Jun 18.

PMID:
27288217
14.

Needle size for vaccination procedures in children and adolescents.

Beirne PV, Hennessy S, Cadogan SL, Shiely F, Fitzgerald T, MacLeod F.

Cochrane Database Syst Rev. 2015 Jun 18;(6):CD010720. doi: 10.1002/14651858.CD010720.pub2. Review. Update in: Cochrane Database Syst Rev. 2018 Aug 09;8:CD010720.

PMID:
26086647
15.
16.

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.

Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW.

Pediatr Infect Dis J. 2017 Feb;36(2):209-215. doi: 10.1097/INF.0000000000001406.

PMID:
27846055
17.

Needle size for vaccination procedures in children and adolescents.

Beirne PV, Hennessy S, Cadogan SL, Shiely F, Fitzgerald T, MacLeod F.

Cochrane Database Syst Rev. 2018 Aug 9;8:CD010720. doi: 10.1002/14651858.CD010720.pub3.

18.

Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process.

Sharma HJ, Patil VD, Lalwani SK, Manglani MV, Ravichandran L, Kapre SV, Jadhav SS, Parekh SS, Ashtagi G, Malshe N, Palkar S, Wade M, Arunprasath TK, Kumar D, Shewale SD.

Vaccine. 2012 Jan 11;30(3):510-6. doi: 10.1016/j.vaccine.2011.11.067. Epub 2011 Nov 26.

PMID:
22119927
19.

Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine.

Desai S, Rathi N, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey AP, Venkateswara Rao J, Narayanappa D, Ghildiyal R, Gogtay NJ, Venugopal P, Palkar S, Munshi R, Bavdekar A, Juvekar S, Ganguly N, Niyogi P, Uttam KG, Kondekar A, Kumbhar D, Mohanlal S, Agarwal MC, Shetty P, Antony K, Gunale B, Dharmadhikari A, Deshpande J, Nalavade U, Sharma D, Bansal A, Tang Y, Flores J, Kulkarni PS.

Vaccine. 2018 Sep 5;36(37):5519-5523. doi: 10.1016/j.vaccine.2018.07.064. Epub 2018 Aug 10.

20.

Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.

Faingezicht I, Avila-Aguerro ML, Cervantes Y, Fourneau M, Clemens SA.

Rev Panam Salud Publica. 2002 Oct;12(4):247-57.

PMID:
12431356

Supplemental Content

Support Center